CO5570664A2 - Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos - Google Patents
Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticosInfo
- Publication number
- CO5570664A2 CO5570664A2 CO05050416A CO05050416A CO5570664A2 CO 5570664 A2 CO5570664 A2 CO 5570664A2 CO 05050416 A CO05050416 A CO 05050416A CO 05050416 A CO05050416 A CO 05050416A CO 5570664 A2 CO5570664 A2 CO 5570664A2
- Authority
- CO
- Colombia
- Prior art keywords
- indan
- dimethyl
- phenyl
- propoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
1.- en la cual R1 y R5 son independientemente seleccionados del grupo que consiste en H y halógeno;R2, R3 y R4 son independientemente seleccionados del grupo que consiste en H, halógeno y J-K en donde:J es un enlace covalente, alquileno o alquenilo; y K es seleccionado del grupo de CO2R8, siendo R8 H o alquilo;R6 es seleccionado del grupo que consiste en H o alquilo;R7 es seleccionado del grupo que consiste en arilo o arilo condensado, dihidro, tetrahidro arilo condensado, heteroarilo, sin substituir o substituidos con cualquier substituyente seleccionado del grupo que consiste en OH, halógeno, alquilo C1-4, alcoxilo C1-4, cicloalquilo C3-6, CF3, OCF3, CN y NO2;y sales y complejos farmacéuticamente aceptables de los mismos.2.- Un compuesto de acuerdo con la reivindicación 1, seleccionado del grupo que consiste en clorhidrato de ácido (E)-3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-acrílico;clorhidrato de ácido 3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de éster etílico del ácido 3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico;clorhidrato de ácido (E)-3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-pent-4-enoico;clorhidrato de ácido 5-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-pentanoico;éster etílico del ácido 5-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetiI-etil-amino)-propoxi]-fenil}-pentanoico; clorhidrato de éster etílico del ácido 3-{4-bromo-3-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico;clorhidrato de ácido 3-{4-bromo-3-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de ácido 3-{2,3-difluor-4-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de éster etílico del ácido 3-{2,3-difluor-4-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42910502P | 2002-11-26 | 2002-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5570664A2 true CO5570664A2 (es) | 2005-10-31 |
Family
ID=32393505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05050416A CO5570664A2 (es) | 2002-11-26 | 2005-05-24 | Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos |
Country Status (33)
Country | Link |
---|---|
US (6) | US7514473B2 (es) |
EP (1) | EP1569892B1 (es) |
JP (1) | JP4489597B2 (es) |
KR (2) | KR20050086786A (es) |
CN (1) | CN1325466C (es) |
AP (1) | AP2113A (es) |
AR (1) | AR042132A1 (es) |
AU (1) | AU2003291157C1 (es) |
BR (1) | BR0316544A (es) |
CA (1) | CA2507226C (es) |
CO (1) | CO5570664A2 (es) |
CY (1) | CY1113083T1 (es) |
DK (1) | DK1569892T3 (es) |
EA (1) | EA009603B1 (es) |
ES (1) | ES2388277T3 (es) |
HK (1) | HK1082914A1 (es) |
IL (1) | IL168704A (es) |
IS (1) | IS2897B (es) |
MA (1) | MA27528A1 (es) |
MX (1) | MXPA05005574A (es) |
MY (1) | MY143244A (es) |
NO (1) | NO332304B1 (es) |
NZ (1) | NZ540275A (es) |
OA (1) | OA12962A (es) |
PE (1) | PE20040845A1 (es) |
PL (1) | PL211571B1 (es) |
PT (1) | PT1569892E (es) |
SI (1) | SI1569892T1 (es) |
TW (1) | TWI316511B (es) |
UA (1) | UA81642C2 (es) |
UY (1) | UY28089A1 (es) |
WO (1) | WO2004047751A2 (es) |
ZA (1) | ZA200504104B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR042132A1 (es) * | 2002-11-26 | 2005-06-08 | Smithkline Beecham Corp | Compuesto de 2- hidroxi -3-(2- aril - 1, 1 - dimetiletilamino) propoxifenilo, composicion farmaceutica que lo comprende y uso del mismo para prepararla |
EP1713758A4 (en) * | 2004-02-06 | 2008-02-13 | Smithkline Beecham Corp | CALCILYTIC COMPOUNDS |
UY30801A1 (es) | 2006-12-18 | 2008-07-03 | Smithkline Beecham Corp | Compuestos calciliticos |
DK2292592T3 (da) | 2008-06-05 | 2012-10-08 | Asahi Kasei Pharma Corp | Sulfonamidforbindelse og anvendelse deraf |
CA2748250A1 (en) * | 2008-12-24 | 2010-07-01 | Daiichi Sankyo Company, Limited | Indanyl compounds |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
WO2015196205A1 (en) * | 2014-06-20 | 2015-12-23 | Glaxosmithkline Llc | Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE298506C (es) | ||||
US643656A (en) * | 1898-09-03 | 1900-02-20 | Francis Keil | Mold for lock-cylinders and key-hubs. |
ES421076A1 (es) | 1973-12-01 | 1976-04-01 | Andreu Sa Dr | Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles. |
ES442062A1 (es) | 1975-10-24 | 1977-04-01 | Andreu Sa Dr | Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos. |
DE2644833A1 (de) * | 1976-10-05 | 1978-04-20 | Boehringer Sohn Ingelheim | Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung |
CH618335A5 (es) * | 1977-05-31 | 1980-07-31 | Arnegger Richard E | |
US4234595A (en) * | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
IT1101724B (it) * | 1978-12-05 | 1985-10-07 | Erba Carlo Spa | Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione |
IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
GB2014968A (en) | 1978-02-24 | 1979-09-05 | Pearson J | Article handling apparatus |
US4495352A (en) * | 1979-02-13 | 1985-01-22 | Mead Johnson & Company | Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols |
ES480066A1 (es) | 1979-04-28 | 1980-04-01 | Especialid Latin Medicam Unive | Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos. |
DE3544172A1 (de) * | 1985-12-13 | 1987-06-19 | Lentia Gmbh | Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung |
FR2601008B1 (fr) * | 1986-07-03 | 1990-03-30 | Sanofi Sa | Procede de synthese stereospecifique de derives de l'indole |
DD298506A5 (de) * | 1988-12-30 | 1992-02-27 | Ernst-Moritz-Arndt-Universitaet Greifswald,De | Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole |
DE4040186A1 (de) | 1989-12-20 | 1991-06-27 | Hoechst Ag | Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
US6818660B2 (en) * | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
NZ332068A (en) | 1996-04-09 | 2001-03-30 | Smithkline Beecham | Alpha, alpha-disubstituted arylalkylamine derivatives as calcilytic compounds |
US20020019440A1 (en) * | 1996-11-05 | 2002-02-14 | Virbac Sa | Aryloxypropanolamine derivatives, method of preparation and applications thereof |
TW483881B (en) * | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
US7202261B2 (en) * | 1996-12-03 | 2007-04-10 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
WO1998044925A1 (en) | 1997-04-04 | 1998-10-15 | Smithkline Beecham Corporation | Calcilytic compounds |
UY24949A1 (es) * | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
DE19913753A1 (de) | 1998-04-01 | 1999-10-07 | Mannesmann Rexroth Ag | Verfahren zur Bildung des Mittelwertes |
PE20000415A1 (es) * | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | Compuestos calciliticos |
AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
EP1104411A4 (en) * | 1998-08-12 | 2002-10-24 | Smithkline Beecham Corp | CALCILYTIC COMPOUNDS |
JP2002522499A (ja) * | 1998-08-12 | 2002-07-23 | スミスクライン・ビーチャム・コーポレイション | カルシウム分解化合物 |
PE20001456A1 (es) * | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
CO5180628A1 (es) | 1999-07-31 | 2002-07-30 | Smithkline Beecham Corp | Compuestos calcioliticos |
US20030018203A1 (en) * | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
MY159417A (en) | 2000-01-24 | 2017-01-13 | Smithkline Beecham Corp | Calcilytic compounds |
KR20030017642A (ko) | 2000-07-21 | 2003-03-03 | 스미스클라인 비참 코포레이션 | 칼실리틱 화합물 |
EP1404654A4 (en) | 2000-10-25 | 2008-12-03 | Smithkline Beecham Corp | CALCILYTIC COMPOUNDS |
EP1383511B1 (en) | 2000-10-25 | 2006-10-25 | SmithKline Beecham Corporation | Calcilytic compounds |
AU2002254136A1 (en) * | 2001-03-08 | 2002-09-24 | Smithkline Beecham Corporation | Pcra helicase inhibitors |
US6864267B2 (en) * | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
AR042132A1 (es) | 2002-11-26 | 2005-06-08 | Smithkline Beecham Corp | Compuesto de 2- hidroxi -3-(2- aril - 1, 1 - dimetiletilamino) propoxifenilo, composicion farmaceutica que lo comprende y uso del mismo para prepararla |
WO2004092121A2 (en) * | 2003-04-07 | 2004-10-28 | Nps Pharmaceuticals, Inc. | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones |
WO2005018561A2 (en) * | 2003-08-20 | 2005-03-03 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
TW200524892A (en) * | 2003-09-24 | 2005-08-01 | Glaxo Group Ltd | Calcilytic compounds |
WO2005030746A1 (en) | 2003-09-24 | 2005-04-07 | Glaxo Group Limited | Calcilytic compounds |
JP2007523076A (ja) * | 2004-02-06 | 2007-08-16 | スミスクライン・ビーチャム・コーポレイション | カルシウム受容体アンタゴニスト化合物 |
NL1025457C1 (nl) | 2004-02-11 | 2005-08-12 | Rudolf Johannes Gerardus Hoorn | Haspelrem. |
WO2006052899A2 (en) | 2004-11-08 | 2006-05-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
WO2006078995A1 (en) | 2005-01-21 | 2006-07-27 | Nitromed, Inc. | Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use |
-
2003
- 2003-11-24 AR ARP030104333A patent/AR042132A1/es not_active Application Discontinuation
- 2003-11-24 UY UY28089A patent/UY28089A1/es unknown
- 2003-11-24 TW TW092132853A patent/TWI316511B/zh not_active IP Right Cessation
- 2003-11-24 MY MYPI20034511A patent/MY143244A/en unknown
- 2003-11-25 EP EP03783752A patent/EP1569892B1/en not_active Expired - Lifetime
- 2003-11-25 EA EA200500878A patent/EA009603B1/ru not_active IP Right Cessation
- 2003-11-25 SI SI200332179T patent/SI1569892T1/sl unknown
- 2003-11-25 CN CNB2003801092068A patent/CN1325466C/zh not_active Expired - Fee Related
- 2003-11-25 AU AU2003291157A patent/AU2003291157C1/en not_active Ceased
- 2003-11-25 KR KR1020057009379A patent/KR20050086786A/ko not_active Application Discontinuation
- 2003-11-25 UA UAA200505005A patent/UA81642C2/ru unknown
- 2003-11-25 OA OA1200500152A patent/OA12962A/en unknown
- 2003-11-25 MX MXPA05005574A patent/MXPA05005574A/es active IP Right Grant
- 2003-11-25 WO PCT/US2003/037461 patent/WO2004047751A2/en active Application Filing
- 2003-11-25 PT PT03783752T patent/PT1569892E/pt unknown
- 2003-11-25 DK DK03783752.3T patent/DK1569892T3/da active
- 2003-11-25 JP JP2004555635A patent/JP4489597B2/ja not_active Expired - Fee Related
- 2003-11-25 PL PL376965A patent/PL211571B1/pl unknown
- 2003-11-25 ES ES03783752T patent/ES2388277T3/es not_active Expired - Lifetime
- 2003-11-25 PE PE2003001196A patent/PE20040845A1/es not_active Application Discontinuation
- 2003-11-25 BR BR0316544-2A patent/BR0316544A/pt active Search and Examination
- 2003-11-25 KR KR1020117025893A patent/KR101142697B1/ko not_active IP Right Cessation
- 2003-11-25 AP AP2005003320A patent/AP2113A/xx active
- 2003-11-25 CA CA2507226A patent/CA2507226C/en not_active Expired - Fee Related
- 2003-11-25 US US10/536,416 patent/US7514473B2/en not_active Expired - Fee Related
- 2003-11-25 NZ NZ540275A patent/NZ540275A/en not_active IP Right Cessation
-
2005
- 2005-05-19 IL IL168704A patent/IL168704A/en not_active IP Right Cessation
- 2005-05-23 MA MA28294A patent/MA27528A1/fr unknown
- 2005-05-24 CO CO05050416A patent/CO5570664A2/es active IP Right Grant
- 2005-06-02 IS IS7880A patent/IS2897B/is unknown
- 2005-06-22 NO NO20053071A patent/NO332304B1/no not_active IP Right Cessation
-
2006
- 2006-02-07 ZA ZA200504104A patent/ZA200504104B/en unknown
- 2006-03-02 HK HK06102773.3A patent/HK1082914A1/xx not_active IP Right Cessation
-
2009
- 2009-02-26 US US12/393,284 patent/US7829594B2/en not_active Expired - Fee Related
-
2010
- 2010-09-30 US US12/894,644 patent/US8399517B2/en not_active Expired - Fee Related
-
2012
- 2012-09-03 CY CY20121100784T patent/CY1113083T1/el unknown
-
2013
- 2013-02-11 US US13/764,126 patent/US8586631B2/en not_active Expired - Fee Related
- 2013-11-01 US US14/069,447 patent/US8980950B2/en not_active Expired - Fee Related
-
2015
- 2015-03-06 US US14/640,711 patent/US9227914B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5570664A2 (es) | Derivados de acidos 2-hidroxi-3(2-indan-2-il-1,1-dimetil-etilamino)-propoxi-fenil-propionico y composiciones farmaceuticas que los contienen como agentes calciliticos | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
CO5170521A1 (es) | Compuestos farmaceuticos de pirimidinona | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
ES2124167B1 (es) | Nuevos derivados del bencimidazol con actividad antihistaminica. | |
PA8494101A1 (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
AR032072A1 (es) | Derivados de quinuclidina novedosos y composiciones medicinales que los contienen | |
CU23132A3 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
AR045859A1 (es) | Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos | |
CO5540286A2 (es) | Derivados naftil indol sustituidos | |
BR0112475A (pt) | N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina | |
AR028985A1 (es) | Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene | |
ES2167710T3 (es) | Tiofenopirimidinas. | |
CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
AR018705A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos. | |
AR006890A1 (es) | Compuestos alquil-4-silil-fenoles y esteres de los mismos como agentes antiateroscleroticos | |
AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
DK1074542T3 (da) | Sulfonamidholdige indolforbindelser | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
NZ307505A (en) | Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | |
AR049464A1 (es) | Antagonistas de receptores de acetilcolina muscarinicos. composiciones farmaceuticas | |
MXPA05007494A (es) | Nuevos compuestos. | |
CO4980859A1 (es) | Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina | |
AR055171A1 (es) | Derivados de carboxamida como antagonistas del receptor muscarinico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |